4.7 Article

In Vitro and In Vivo Effect of pH-Sensitive PLGA-TPGS-Based Hybrid Nanoparticles Loaded with Doxorubicin for Breast Cancer Therapy

Journal

PHARMACEUTICS
Volume 14, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14112394

Keywords

doxorubicin; lipid-polymer hybrid nanoparticles; TPGS; antitumor activity; pH-sensitive; alpha-tocopherol succinate; drug delivery system

Funding

  1. Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG-Brazil) [PPM-00387-17, PPM-00456-17]
  2. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq-Brazil) [429703/2018-0, 310316/2020-0, 427798/2018-3]
  3. National Institutes of Health [5P20GM103542]

Ask authors/readers for more resources

This study developed a novel hybrid nanoparticle for the treatment of breast cancer by combining the advantages of liposomes and polymeric nanoparticles. The nanoparticles demonstrated significant reductions in cell viability and migration, as well as enhanced cellular uptake, leading to effective inhibition of tumor growth. The increased accumulation of drugs in the tumor area, along with the synergic combination with TS, further improved the antitumor efficacy.
Doxorubicin (DOX) is an antineoplastic agent clinically employed for treating breast cancer patients. Despite its effectiveness, its inherent adverse toxic side effects often limit its clinical application. To overcome these drawbacks, lipid-polymer hybrid nanoparticles (LPNP) arise as promising nanoplatforms that combine the advantages of both liposomes and polymeric nanoparticles into a single delivery system. Alpha-tocopherol succinate (TS) is a derivative of vitamin E that shows potent anticancer mechanisms, and it is an interesting approach as adjuvant. In this study, we designed a pH-sensitive PLGA-polymer-core/TPGS-lipid-shell hybrid nanoparticle, loaded with DOX and TS (LPNP_TS-DOX). Nanoparticles were physicochemically and morphologically characterized. Cytotoxicity studies, migration assay, and cellular uptake were performed in 4T1, MCF-7, and MDAMB-231 cell lines. Antitumor activity in vivo was evaluated in 4T1 breast tumor-bearing mice. In vitro studies showed a significant reduction in cell viability, cell migration, and an increase in cellular uptake for the 4T1 cell line compared to free DOX. In vivo antitumor activity showed that LPNPTS-DOX was more effective in controlling tumor growth than other treatments. The high cellular internalization and the pH-triggered payload release of DOX lead to the increased accumulation of the drugs in the tumor area, along with the synergic combination with TS, culminating in greater antitumor efficacy. These data support LPNP-TS-DOX as a promising drug delivery system for breast cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available